Perturbation of p38α MAPK as a Novel Strategy to Effectively Sensitize Chronic Myeloid Leukemia Cells to Therapeutic BCR-ABL Inhibitors

Perturbation of p38α MAPK as a Novel Strategy to Effectively Sensitize Chronic Myeloid Leukemia Cells to Therapeutic BCR-ABL Inhibitors

Chronic myeloid leukemia (CML) is a hematopoietic malignancy characterized by the presence of the BCR-ABL oncogene. Therapeutic regimens with tyrosine kinase inhibitors (TKIs) specifically targeting BCR-ABL have greatly improved overall survival of CML. However, drug intolerance and related toxicity...

Full description

Bibliographic Details
Main Authors: Yi-Hue Kuo, Shih-Hsiang Wei, Jie-Hau Jiang, Yueh-Shih Chang, Mei-Yin Liu, Shu-Ling Fu, Chi-Ying F. Huang, Wey-Jinq Lin
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:International Journal of Molecular Sciences
Subjects:
chronic myeloid leukemia
combined therapy
imatinib
dasatinib
p38 MAPK
Online Access:https://www.mdpi.com/1422-0067/22/22/12573

Internet

https://www.mdpi.com/1422-0067/22/22/12573

Similar Items